Furthermore, the IHC results revealed that TSHR is highly expressed in differentiated thyroid cancers, including both papillary (PTC) and follicular (FTC) thyroid carcinoma, while exhibiting comparatively low expression in medullary thyroid cancer (MTC) (Figure 1C,D), aligning with earlier reports from other researchers.[32] These findings demonstrated that TSHR is a promising target for CAR‐T therapy in differentiated thyroid cancer. Here, TSHR is linked to thyroid cancer, nonmedullary, 2.